A Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting Stent System Medtronic RESOLUTE ONYX Core (2.25 mm - 4.0 mm) Clinical Study
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Zotarolimus (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- Sponsors Medtronic
- 22 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jul 2016, as reported by ClinicalTrials.gov.
- 17 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 Sep 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.